The generation and use of transgenic and gene-targeted mice has become an essential technology for basic cancer research, as well as for other areas of basic biomedical research. Therefore, this facility serves two critical functions within the Cancer Center. First, the Animal Facility provides convenient, affordable and high quality animal care and maintenance to Cancer Center investigators who use transgenic, mutant and other experimental mice in their research. The support for this Facility provided by the Cancer Center, as well as by the University, results in animal maintenance charges that are relatively affordable, which is a prerequisite for genetic studies using large numbers of transgenic and mutant mice. Second, the Facility operates a transgenic and chimeric mouse production service, which allows all Cancer Center investigators to generate new strains of transgenic mice or perform gene targeting (e.g., gene knockout) studies. The Facility provides technical advice on the design and construction of transgenes and gene-targeting vectors. DNA constructs for transgenesis, and genetically modified ES cell lines are produced by individual Cancer Center investigators, then delivered to the facility, where they are injected into mouse eggs or blastocysts, respectively. The resulting mice are then returned to the individual investigators for further analysis and breeding. The Facility also plans to provide cryopreservation of mouse embryos, and to produce new wild type ES cell lines for use by investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013696-30
Application #
6616882
Study Section
Project Start
2002-07-23
Project End
2003-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
30
Fiscal Year
2002
Total Cost
$296,752
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Jauregui, Ruben; Park, Karen Sophia; Duong, Jimmy K et al. (2018) Quantitative progression of retinitis pigmentosa by optical coherence tomography angiography. Sci Rep 8:13130
O'Neil, Daniel S; Prigerson, Holly G; Mmoledi, Keletso et al. (2018) Informal Caregiver Challenges for Advanced Cancer Patients During End-of-Life Care in Johannesburg, South Africa and Distinctions Based on Place of Death. J Pain Symptom Manage 56:98-106
Liu, Katherine Y; Sengillo, Jesse D; Velez, Gabriel et al. (2018) Missense mutation in SLIT2 associated with congenital myopia, anisometropia, connective tissue abnormalities, and obesity. Orphanet J Rare Dis 13:138
Koch, Susanne F; Tsang, Stephen H (2018) Success of Gene Therapy in Late-Stage Treatment. Adv Exp Med Biol 1074:101-107
DiCarlo, James E; Mahajan, Vinit B; Tsang, Stephen H (2018) Gene therapy and genome surgery in the retina. J Clin Invest 128:2177-2188
Wert, Katherine J; Velez, Gabriel; Cross, Madeline R et al. (2018) Extracellular superoxide dismutase (SOD3) regulates oxidative stress at the vitreoretinal interface. Free Radic Biol Med 124:408-419
Lee, Andreia; CingĂ–z, Oya; Sabo, Yosef et al. (2018) Characterization of interaction between Trim28 and YY1 in silencing proviral DNA of Moloney murine leukemia virus. Virology 516:165-175
Schrank, Benjamin R; Aparicio, Tomas; Li, Yinyin et al. (2018) Nuclear ARP2/3 drives DNA break clustering for homology-directed repair. Nature 559:61-66
Proto, Jonathan D; Doran, Amanda C; Gusarova, Galina et al. (2018) Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution. Immunity 49:666-677.e6
Hernandez, Celine; Huebener, Peter; Pradere, Jean-Philippe et al. (2018) HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis. J Clin Invest 128:2436-2451

Showing the most recent 10 out of 331 publications